Halley E Gilbert insider trades: Arcutis Biotherapeutics (ARQT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Halley reports to the SEC
and 1 more company
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | ARQT | ↓ Sell | 16,532 | $27.55 | $455K | Direct | Nov 21, 2025 (1d) |
| Jun 3, 2024 | PCVX | ↓ Sell | 18,200 | $73.00 | $1.3M | Direct | Jun 5, 2024 (2d) |
| Feb 21, 2020 | IRWD | ↓ Sell10b5-1 | 15,328 | $11.63 | $178K | Direct | Feb 25, 2020 (4d) |
| Jan 31, 2020 | IRWD | ↓ Sell | 60,000 | $12.05 | $723K | Direct | Feb 4, 2020 (4d) |
| Jul 26, 2019 | IRWD | ↓ Sell | 20,000 | $10.00 | $200K | Direct | Jul 30, 2019 (4d) |
| May 10, 2019 | IRWD | ↓ Sell10b5-1 | 4,055 | $10.53 | $43K | Direct | May 14, 2019 (4d) |
| Feb 21, 2019 | IRWD | ↓ Sell10b5-1 | 10,242 | $14.31 | $147K | Direct | Feb 22, 2019 (1d) |
| Jul 3, 2018 | IRWD | ↓ Sell | 29,551 | $19.75 | $584K | Direct | Jul 5, 2018 (2d) |
| Feb 21, 2018 | IRWD | ↓ Sell10b5-1 | 7,741 | $14.66 | $113K | Direct | Feb 22, 2018 (1d) |
| Jun 22, 2017 | IRWD | ↓ Sell | 35,000 | $19.75 | $691K | Direct | Jun 26, 2017 (4d) |
| Feb 22, 2017 | IRWD | ↓ Sell10b5-1 | 5,039 | $16.94 | $85K | Direct | Feb 24, 2017 (2d) |
| Feb 14, 2017 | IRWD | ↓ Sell | 37,385 | $16.75 | $626K | Direct | Feb 15, 2017 (1d) |
| Nov 11, 2016 | IRWD | ↓ Sell | 14,000 | $16.75 | $235K | Direct | Nov 15, 2016 (4d) |
| May 25, 2016 | IRWD | ↓ Sell | 15,865 | $12.19 | $193K | Direct | May 27, 2016 (2d) |
| May 25, 2016 | IRWD | ↓ Sell | 4,410 | $12.19 | $54K | Direct | May 27, 2016 (2d) |
| Feb 24, 2016 | IRWD | ↓ Sell10b5-1 | 2,778 | $8.50 | $24K | Direct | Feb 26, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Halley E Gilbert's insider trades
Halley E Gilbert is a director at Arcutis Biotherapeutics (ARQT). Since Feb 24, 2016, Halley has reported no open-market purchases and 16 sales worth $5.7M on SEC Form 4. In the last 12 months: 1 sale ($455K).
6 sales (10% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (36 filings), option exercises (10 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.